2-(benzyloxy)-3-hydroxybenzaldehyde | 86734-60-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(benzyloxy)-3-hydroxybenzaldehyde
• 英文别名: 3-hydroxy-2-phenylmethoxybenzaldehyde
• CAS: 86734-60-3
• 化学式: C₁₄H₁₂O₃
• 分子量: 228.247
• InChiKey: CCHSJXWROPKNDR-UHFFFAOYSA-N

物化性质

• 熔点：
  90-91 °C(Solv: benzene (71-43-2))
• 沸点：
  170-180 °C(Press: 0.1 Torr)
• 密度：
  1.238±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(benzyloxy)-3-hydroxybenzaldehyde 在 palladium on activated charcoal 4-二甲氨基吡啶 、 sodium hydroxide 、 四丁基氟化铵 、 sodium methylate 、 potassium carbonate 、 三乙胺 、 环己烯 作用下， 以 四氢呋喃 、 吡啶 、 甲醇 、 乙醇 、 二氯甲烷 、 xylene 为溶剂， 反应 49.0h， 生成 8-(4-Oxo-1-phenyl-1,3,8-triaza-spiro[4.5]dec-8-ylmethyl)-7,8-dihydro-3H-6,9-dioxa-3-aza-cyclopenta[a]naphthalene-2-carboxylic acid methyl ester
  参考文献：
  名称：

  Novel indolodioxanes with antihypertensive effects: potent ligands for the 5-HT1A receptor

  摘要：

  The synthesis and biological evaluation of a new family of tricyclic indolodioxanes is described. These compounds all contain the 2,3-dihydro-7H-1,4-dioxino[2,3-e]indole nucleus and bear substituents at the 2 and/or 8 positions. Thirteen members of this class were prepared and shown to be potent ligands for the 5-HTA receptor, with several compounds displaying subnanomolar inhibition constants. These compounds also bind to the dopamine D-2 receptor, but generally with higher inhibition constants than those for 5-HT1A. Certain members of this novel structural class show in vivo activity in the mouse hypothermia assay. One of these compounds, U-86192A, has been shown to have antihypertensive effects in the cat, completely eliminating sympathetic nerve discharge at 1 mg/kg iv and lowering mean arterial pressure to 50% pretreatment levels. These effects can be reversed by the administration of spiperone, indicating that U-86192A is acting via a central serotonergic mechanism.

  DOI：

  10.1021/jm00094a021
• 作为产物：
  描述：

  2-(benzyloxy)-3-(methoxymethoxy)benzaldehyde 在 盐酸 、 水 作用下， 以 1,4-二氧六环 为溶剂， 以548 mg的产率得到2-(benzyloxy)-3-hydroxybenzaldehyde
  参考文献：
  名称：

  通过路易斯酸催化的CH官能团快速合成苯并吡喃：通过邻位取代基显着增强反应性

  摘要：

  通过路易斯酸催化的CH官能团可以快速构建苯并吡喃骨架。在这个过程中，[1,5]氢化移和6-内环化接连不断，得到苯并吡喃。烷氧基邻位取代基的存在显着提高了反应性，以较短的反应时间以优异的化学产率提供了所需的化合物。

  DOI：

  10.1021/ol100316k

文献信息

• Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
  申请人：——

  公开号：US20040024034A1

  公开（公告）日：2004-02-05

  Compounds represented by the following (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl or cycloalkyl-alkyl, R2 is H, alkyl or haloalkyl, the polymethylene chain (II), is saturated or may contain a carbon-carbon double bond, while n is 2, 3, 4, W is O or S, Y is an unsubsituted or substituted phenylene, naphthylene or 1, 2, 3, 4 tetrahydronaphthylene, R3 is H, alkyl or haloalkyl. R4 is H, alkyl, haloalkyl or a substituted or unsubstituted benzyl, are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.

  以下化合物（I）及其药用可接受的盐、溶剂化合物和水合物，其中R1是未取代或取代的芳基、杂环芳基、环烷基、芳基-烷基、杂环芳基-烷基或环烷基-烷基，R2是H、烷基或卤代烷基，聚亚甲基链（II）饱和或可能含有碳-碳双键，n为2、3、4，W为O或S，Y是未取代或取代的苯基、萘基或1,2,3,4-四氢萘基，R3是H、烷基或卤代烷基。R4是H、烷基、卤代烷基或取代或未取代的苄基，用于调节过氧化物酶体增殖物激活受体，特别是在糖尿病治疗中是有用的。
• Regioselective mono-O-alkylation of same pyrocatechoxide dianions
  作者：Satinder V. Kessar、Yash P. Gupta、Taj Mohammad、Manju Goyal、Kewal K. Sawal

  DOI：10.1039/c39830000400

  日期：——

  In dimethyl sulphoxide the dianions derived from 2,3- or 3,4-dihydroxybenzaldehydes and 4-methylesculetin afford products corresponding to alkylation at the less acidic site while the monoanions give the isomeric phenols.

  在二甲亚砜中，衍生自2,3-或3,4-二羟基苯甲醛和4-甲基七丁烯的二价阴离子在较低的酸性位点提供对应于烷基化的产物，而单阴离子给出异构体的苯酚。
• Heterocyclcarboxamide derivatives and their use as therapeutic agents
  申请人：Knoll Aktiengesellschaft

  公开号：US05935973A1

  公开（公告）日：1999-08-10

  Compounds of formula I ##STR1## and pharmaceutically acceptable salts thereof in which A is methylene or O; B is methylene or O; g is 0,1,2,3 or 4; R.sub.1 is an optional substituent; U is an alkylene chain optionally substituted by one or more alkyl; Q represents a divalent group containing nitrogen atoms; and T represents CO.HET, have utility in the treatment of central nervous system disorders, for example depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, Parkinson's disease, obesity, hypertension, Tourette's syndrome, sexual dysfunction, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, senile dementia, obsessive-compulsive behavior, panic attacks, social phobias, eating disorders and anorexia, cardiovascular and cerebrovascular disorders, non-insulin dependent diabetes mellitus, hyperglycaemia, constipation, arrhythmia, disorders of the neuroendocrine system, stress, prostatic hypertrophy, and spasticity.

  化合物的化学式I ##STR1## 及其药用盐，在其中A为亚甲基或氧；B为亚甲基或氧；g为0,1,2,3或4；R.sub.1为可选取代基；U为一种烷基链，可选择地被一个或多个烷基取代；Q代表含氮原子的二价基团；T代表CO.HET，在治疗中枢神经系统疾病方面具有用途，例如抑郁症、焦虑、精神病（例如精神分裂症）、迟发性运动障碍、帕金森病、肥胖症、高血压、托瑞特综合症、性功能障碍、药物成瘾、药物滥用、认知障碍、阿尔茨海默病、老年性痴呆、强迫行为、恐慌发作、社交恐惧症、进食障碍和厌食症、心血管和脑血管疾病、非胰岛素依赖型糖尿病、高血糖、便秘、心律失常、神经内分泌系统疾病、应激、前列腺肥大和痉挛性疾病。
• [EN] HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：SPINIFEX PHARM PTY LTD

  公开号：WO2015003223A1

  公开（公告）日：2015-01-15

  The present invention relates generally to compounds that are useful in antagonizing the angiotensin II type 2 (AT2) receptor. More particularly, the invention relates to substituted isoquinoline compounds and their use as AT2 receptor antagonists. Pharmaceutical compositions comprising the compounds and their use in modulating the AT2 receptor and therapies that require modulation of the AT2 receptor are described.

  本发明一般涉及对抗血管紧张素II型2（AT2）受体的化合物。更具体地，本发明涉及取代异喹啉化合物及其用作AT2受体拮抗剂的用途。描述了包含这些化合物的药物组合物以及它们在调节AT2受体和需要调节AT2受体的治疗中的用途。
• (Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors
  申请人：Allen Darin A.

  公开号：US06867200B1

  公开（公告）日：2005-03-15

  The present invention provides novel compounds of the Formula (I): A-B, its prodrug forms, or pharmaceutically acceptable salts thereof, wherein A represents a saturated, unsaturated, or a partially unsaturated bicyclic heterocyclic ring structure, and B represents an aryl or a heteroaryl group. Preferred compounds of the present invention comprise a benzimidazole or indole nucleus. The compounds of this invention are inhibitors of serine proteases, Urokinase (uPA), Factor Xa (FXa), and/or Factor VIIa (FVIIa), and have utility as anti cancer agents and/or as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals.

  本发明提供了Formula (I)的新化合物：A-B，其前药形式，或其药学上可接受的盐，其中A代表饱和、不饱和或部分不饱和的双环杂环环结构，B代表芳基或杂芳基团。本发明的首选化合物包括苯并咪唑或吲哚核。本发明的化合物是丝氨酸蛋白酶、尿激酶（uPA）、Xa因子（FXa）和/或VIIa因子（FVIIa）的抑制剂，并具有作为抗癌剂和/或抗凝血剂的用途，用于治疗或预防哺乳动物的血栓栓塞疾病。